 | Up a level |
2022
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P. A., Nekljudova, V., Denkert, C. and Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann. Oncol., 33 (11). S. 1149 - 1159. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2018
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2011
von Minckwitz, G., Kaufmann, M., Kuemmel, S., Fasching, P. A., Eiermann, W., Blohmer, J. U., Costa, S. D., Hilfrich, J., Jackisch, C., Gerber, B., Barinoff, J., Huober, J., Hanusch, C., Konecny, G., Fett, W., Stickeler, E., Harbeck, N., Mehta, K., Loibl, S. and Untch, M. (2011). Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane plus /-Trastuzumab Containing Chemotherapy. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445